Hepatitis Monthly

Published by: Kowsar

Genomic Diversity of Hepatitis B Virus Infection Associated With Fulminant Hepatitis B Development

Thomas Mina 1 , Samad Amini-Bavil-Olyaee 2 , Frank Tacke 3 , Piet Maes 1 , Marc Van Ranst 1 and Mahmoud Reza Pourkarim 1 , 4 , *
Authors Information
1 Department of Microbiology and Immunology, Laboratory of Clinical and Epidemiological Virology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium
2 Department of Molecular Microbiology and Immunology, Harlyne J. Norris Cancer Research Tower, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
3 Department of Medicine III, RWTH-University Hospital Aachen, Aachen, Germany
4 Blood Transfusion Research Centre, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran
Article information
  • Hepatitis Monthly: June 2015, 15 (6); e29477
  • Published Online: June 23, 2015
  • Article Type: Review Article
  • Received: April 23, 2015
  • Accepted: May 25, 2015
  • DOI: 10.5812/hepatmon.29477v2

To Cite: Mina T, Amini-Bavil-Olyaee S, Tacke F, Maes P, Van Ranst M, et al. Genomic Diversity of Hepatitis B Virus Infection Associated With Fulminant Hepatitis B Development, Hepat Mon. 2015 ;15(6):e29477. doi: 10.5812/hepatmon.29477v2.

Copyright: Copyright © 2015, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Rakela J, Lange SM, Ludwig J, Baldus WP. Fulminant hepatitis: Mayo Clinic experience with 34 cases. Mayo Clin Proc. 1985; 60(5): 289-92[PubMed]
  • 2. Polson J, Lee WM, American Association for the Study of Liver D. AASLD position paper: the management of acute liver failure. Hepatology. 2005; 41(5): 1179-97[DOI][PubMed]
  • 3. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002; 137(12): 947-54[PubMed]
  • 4. Trey C, Lipworth L, Chalmers TC, Davidson CS, Gottlieb LS, Popper H, et al. Fulminant hepatic failure. Presumable contribution to halothane. N Engl J Med. 1968; 279(15): 798-801[DOI][PubMed]
  • 5. Bernuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology. 1986; 6(4): 648-51[PubMed]
  • 6. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993; 342(8866): 273-5[PubMed]
  • 7. Gimson AE, O'Grady J, Ede RJ, Portmann B, Williams R. Late onset hepatic failure: clinical, serological and histological features. Hepatology. 1986; 6(2): 288-94[PubMed]
  • 8. Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009; 49(5 Suppl)-21[DOI][PubMed]
  • 9. Panassie L, Borentain P, Nafati C, Bernardin G, Doudier B, Thibault V, et al. Fatal fulminant primary hepatitis B virus infections with G1896A precore viral mutants in southeastern France. Clin Res Hepatol Gastroenterol. 2012; 36(1)-8[DOI][PubMed]
  • 10. O'Grady JG. Acute liver failure. Postgrad Med J. 2005; 81(953): 148-54[DOI][PubMed]
  • 11. Jayakumar S, Chowdhury R, Ye C, Karvellas CJ. Fulminant viral hepatitis. Crit Care Clin. 2013; 29(3): 677-97[DOI][PubMed]
  • 12. Hadem J, Tacke F, Bruns T, Langgartner J, Strnad P, Denk GU, et al. Etiologies and outcomes of acute liver failure in Germany. Clin Gastroenterol Hepatol. 2012; 10(6): 664-9 e2[DOI][PubMed]
  • 13. Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012; 42(7): 627-36[DOI][PubMed]
  • 14. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol. 2006; 4(9): 1076-81[DOI][PubMed]
  • 15. Lee WM. Acute liver failure. N Engl J Med. 1993; 329(25): 1862-72[DOI][PubMed]
  • 16. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013; 144(7): 1426-37[DOI][PubMed]
  • 17. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002; 2(7): 395-403[PubMed]
  • 18. Echevarria JM, Avellon A. Hepatitis B virus genetic diversity. J Med Virol. 2006; 78 Suppl 1-42[DOI][PubMed]
  • 19. Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res. 2007; 127(2): 164-76[DOI][PubMed]
  • 20. Chotiyaputta W, Lok AS. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol. 2009; 6(8): 453-62[DOI][PubMed]
  • 21. Pourkarim MR, Amini-Bavil-Olyaee S, Verbeeck J, Lemey P, Zeller M, Rahman M, et al. Molecular evolutionary analysis and mutational pattern of full-length genomes of hepatitis B virus isolated from Belgian patients with different clinical manifestations. J Med Virol. 2010; 82(3): 379-89[DOI][PubMed]
  • 22. Chen L, Zheng CX, Lin MH, Huang ZX, Chen RH, Li QG, et al. Distinct quasispecies characteristics and positive selection within precore/core gene in hepatitis B virus HBV associated acute-on-chronic liver failure. J Gastroenterol Hepatol. 2013; 28(6): 1040-6[DOI][PubMed]
  • 23. Pourkarim MR, Lemey P, Amini-Bavil-Olyaee S, Maes P, Van Ranst M. Novel hepatitis B virus subgenotype A6 in African-Belgian patients. J Clin Virol. 2010; 47(1): 93-6[DOI][PubMed]
  • 24. Pourkarim MR, Amini-Bavil-Olyaee S, Kurbanov F, Van Ranst M, Tacke F. Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions. World J Gastroenterol. 2014; 20(23): 7152-68[DOI][PubMed]
  • 25. Zoulim F, Berthillon P, Guerhier FL, Seigneres B, Germon S, Pichoud C, et al. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies. J Gastroenterol Hepatol. 2002; 17 Suppl-3[PubMed]
  • 26. Kramvis A, Arakawa K, Yu MC, Nogueira R, Stram DO, Kew MC. Relationship of serological subtype, basic core promoter and precore mutations to genotypes/subgenotypes of hepatitis B virus. J Med Virol. 2008; 80(1): 27-46[DOI][PubMed]
  • 27. Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat. 2005; 12(5): 456-64[DOI][PubMed]
  • 28. Molecular modelling of hepatitis B virus polymerase and adefovir resistance identifies three clusters of mutations. Hepatology. : 246A
  • 29. Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology. 2004; 47(6): 289-309[DOI][PubMed]
  • 30. Okamoto H, Imai M, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M. Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr. J Virol. 1987; 61(10): 3030-4[PubMed]
  • 31. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat. 1997; 4 Suppl 1: 11-20[PubMed]
  • 32. Peterson DL, Paul DA, Lam J, Tribby ,I, Achord DT. Antigenic structure of hepatitis B surface antigen: identification of the "d" subtype determinant by chemical modification and use of monoclonal antibodies. J Immunol. 1984; 132(2): 920-7[PubMed]
  • 33. Pourkarim MR, Sharifi Z, Soleimani A, Amini-Bavil-Olyaee S, Elsadek Fakhr A, Sijmons S, et al. Evolutionary analysis of HBV "S" antigen genetic diversity in Iranian blood donors: a nationwide study. J Med Virol. 2014; 86(1): 144-55[DOI][PubMed]
  • 34. Pineda-Pena AC, Faria NR, Mina T, Amini-Bavil-Olyaee S, Alavian SM, Lemey P, et al. Epidemiological history and genomic characterization of non-D1 HBV strains identified in Iran. J Clin Virol. 2015; 63: 38-41[DOI][PubMed]
  • 35. Tamada Y, Yatsuhashi H, Masaki N, Nakamuta M, Mita E, Komatsu T, et al. Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B. Gut. 2012; 61(5): 765-73[DOI][PubMed]
  • 36. Suzuki Y, Kobayashi M, Ikeda K, Suzuki F, Arfase Y, Akuta N, et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol. 2005; 76(1): 33-9[DOI][PubMed]
  • 37. McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int. 2009; 3(2): 334-42[DOI][PubMed]
  • 38. Shi YH. Correlation between hepatitis B virus genotypes and clinical outcomes. Jpn J Infect Dis. 2012; 65(6): 476-82[PubMed]
  • 39. Inoue J, Ueno Y, Kawamura K, Yamamoto T, Mano Y, Miura M, et al. Association between S21 substitution in the core protein of hepatitis B virus and fulminant hepatitis. J Clin Virol. 2012; 55(2): 147-52[DOI][PubMed]
  • 40. Gomes-Gouvea MS, Soares MC, Bensabath G, de Carvalho-Mello IM, Brito EM, Souza OS, et al. Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region. J Gen Virol. 2009; 90: 2638-43[DOI][PubMed]
  • 41. Casey JL, Niro GA, Engle RE, Vega A, Gomez H, McCarthy M, et al. Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis. 1996; 174(5): 920-6[PubMed]
  • 42. Wai CT, Fontana RJ, Polson J, Hussain M, Shakil AO, Han SH, et al. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat. 2005; 12(2): 192-8[DOI][PubMed]
  • 43. Victoria Fda S, Oliveira CM, Victoria MB, Victoria CB, Ferreira LC. Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia. Braz J Infect Dis. 2008; 12(1): 27-37[PubMed]
  • 44. Baig S, Siddiqui AA, Ahmed W, Qureshi H, Arif A. The association of complex liver disorders with HBV genotypes prevalent in Pakistan. Virol J. 2007; 4: 128[DOI][PubMed]
  • 45. Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut. 2005; 54(7): 1009-13[DOI][PubMed]
  • 46. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005; 365(9454): 123-9[DOI][PubMed]
  • 47. Pourkarim MR, Lemey P, Amini-Bavil-Olyaee S, Houspie L, Verbeeck J, Rahman M, et al. Molecular characterization of hepatitis B virus strains circulating in Belgian patients co-infected with HIV and HBV: overt and occult infection. J Med Virol. 2011; 83(11): 1876-84[DOI][PubMed]
  • 48. Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H. Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology. 1993; 194(1): 137-48[DOI][PubMed]
  • 49. Bartholomeusz A, Locarnini S. Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype. Hepatology. 2001; 34(2): 432-5[DOI][PubMed]
  • 50. Kitab B, Essaid El Feydi A, Afifi R, Trepo C, Benazzouz M, Essamri W, et al. Variability in the precore and core promoter regions of HBV strains in Morocco: characterization and impact on liver disease progression. PLoS One. 2012; 7(8)[DOI][PubMed]
  • 51. Wright TL, Mamish D, Combs C, Kim M, Donegan E, Ferrell L, et al. Hepatitis B virus and apparent fulminant non-A, non-B hepatitis. Lancet. 1992; 339(8799): 952-5[PubMed]
  • 52. Sterneck M, Kalinina T, Gunther S, Fischer L, Santantonio T, Greten H, et al. Functional analysis of HBV genomes from patients with fulminant hepatitis. Hepatology. 1998; 28(5): 1390-7[DOI][PubMed]
  • 53. Kalinina T, Riu A, Fischer L, Will H, Sterneck M. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. Hepatology. 2001; 34(2): 385-94[DOI][PubMed]
  • 54. Bock CT, Tillmann HL, Maschek HJ, Manns MP, Trautwein C. A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology. 1997; 113(6): 1976-82[PubMed]
  • 55. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology. 1998; 27(1): 213-22[DOI][PubMed]
  • 56. Bagaglio S, Albarello L, Biswas P, Uberti-Foppa C, Fortis C, Morsica G. Virological pattern of hepatitis B infection in an HIV-positive man with fatal fulminant hepatitis B: a case report. J Med Case Rep. 2009; 3: 110[DOI][PubMed]
  • 57. Pollicino T, Zanetti AR, Cacciola I, Petit MA, Smedile A, Campo S, et al. Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. Hepatology. 1997; 26(2): 495-9[DOI][PubMed]
  • 58. Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol. 2014; 61(2): 408-17[DOI][PubMed]
  • 59. Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med. 1995; 122(4): 241-8[PubMed]
  • 60. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest. 1996; 98(10): 2268-76[DOI][PubMed]
  • 61. Parekh S, Zoulim F, Ahn SH, Tsai A, Li J, Kawai S, et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol. 2003; 77(12): 6601-12[PubMed]
  • 62. Amini-Bavil-Olyaee S, Vucur M, Luedde T, Trautwein C, Tacke F. Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains. J Virol. 2010; 84(2): 1026-33[DOI][PubMed]
  • 63. Zheng Y, Li J, Ou JH. Regulation of hepatitis B virus core promoter by transcription factors HNF1 and HNF4 and the viral X protein. J Virol. 2004; 78(13): 6908-14[DOI][PubMed]
  • 64. Sendi H, Mehrab-Mohseni M, Zali MR, Norder H, Magnius LO. T1764G1766 core promoter double mutants are restricted to Hepatitis B virus strains with an A1757 and are common in genotype D. J Gen Virol. 2005; 86: 2451-8[DOI][PubMed]
  • 65. Gerolami R, Henry M, Borentain P, Colson P, Botta D, Tamalet C. Fulminant hepatitis B associated with a specific insertion in the basal core promoter region of hepatitis B virus DNA after immunosuppressive treatment. Clin Infect Dis. 2005; 40(4)-7[DOI][PubMed]
  • 66. Imamura T, Yokosuka O, Kurihara T, Kanda T, Fukai K, Imazeki F, et al. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. Gut. 2003; 52(11): 1630-7[PubMed]
  • 67. Hou J, Lin Y, Waters J, Wang Z, Min J, Liao H, et al. Detection and significance of a G1862T variant of hepatitis B virus in Chinese patients with fulminant hepatitis. J Gen Virol. 2002; 83: 2291-8[PubMed]
  • 68. Kusakabe A, Tanaka Y, Mochida S, Nakayama N, Inoue K, Sata M, et al. Case-control study for the identification of virological factors associated with fulminant hepatitis B. Hepatol Res. 2009; 39(7): 648-56[DOI][PubMed]
  • 69. Sugiyama M, Tanaka Y, Kurbanov F, Nakayama N, Mochida S, Mizokami M. Influences on hepatitis B virus replication by a naturally occurring mutation in the core gene. Virology. 2007; 365(2): 285-91[DOI][PubMed]
  • 70. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology. 2002; 293(2): 305-13
  • 71. de Man RA, Bartholomeusz AI, Niesters HG, Zondervan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol. 1998; 29(4): 669-75[PubMed]
  • 72. Peters MG, Singer G, Howard T, Jacobsmeyer S, Xiong X, Gibbs CS, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation. 1999; 68(12): 1912-4[PubMed]
  • 73. Kaneko M, Uchida T, Moriyama M, Arakawa Y, Shikata T, Gotoh K, et al. Probable implication of mutations of the X open reading frame in the onset of fulminant hepatitis B. J Med Virol. 1995; 47(3): 204-8[PubMed]
  • 74. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on chronic liver failure. J Hepatol. 2012; 57(6): 1336-48[DOI][PubMed]
  • 75. Laurenti R, Giovannangeli F, Gubinelli E, Viviano MT, Errico A, Leoni L, et al. Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients. Clin Dev Immunol. 2013; 2013: 410521[DOI][PubMed]
  • 76. Cantini F, Boccia S, Goletti D, Iannone F, Leoncini E, Panic N, et al. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-alpha) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. Int J Rheumatol. 2014; 2014: 926836[DOI][PubMed]
  • 77. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol. 2008; 159(6): 1217-28[DOI][PubMed]
  • 78. European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1): 167-85[DOI][PubMed]
  • 79. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989; 97(2): 439-45[PubMed]
  • 80. Wiegand J, Wedemeyer H, Franke A, Rossler S, Zeuzem S, Teuber G, et al. Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. J Viral Hepat. 2014; 21(10): 744-50[DOI][PubMed]
  • 81. Amini-Bavil-Olyaee S, Trautwein C, Tacke F. Relevance of hepatitis B virus genome variability in organ transplantation. Hepat Mon. 2007; 7(1): 35-41
  • 82. Yu JW, Sun LJ, Yan BZ, Kang P, Zhao YH. Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver Int. 2011; 31(4): 499-506[DOI][PubMed]
  • 83. Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006; 13(4): 256-63[DOI][PubMed]
  • 84. Tillmann HL, Patel K. Therapy of acute and fulminant hepatitis B. Intervirology. 2014; 57(3-4): 181-8[DOI][PubMed]
  • 85. Wu TJ, Chen TC, Wang F, Chan KM, Soong RS, Chou HS, et al. Large fragment pre-S deletion and high viral load independently predict hepatitis B relapse after liver transplantation. PLoS One. 2012; 7(2)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader